Fentanyl and Rocuronium for Tracheal Intubation in Newborns (NEORIN)
Effect of the Association of Fentanyl and Rocuronium on First-Attempt Success Rate of Tracheal Intubation in Newborns: A Randomized Clinical Trial
Tracheal intubation is a common and critical procedure in neonatal intensive care units (NICU). Despite its clinical importance, first-attempt success rates remain low (approximately 50%), and adverse events - including oxygen desaturation, bradycardia, and airway trauma - are frequent. Premedication with neuromuscular blocking agents has been associated with improved intubation conditions and fewer adverse events in neonates.
This randomized, double-blind, parallel-group clinical trial (NEORIN) aims to evaluate whether the addition of rocuronium (0,6 mg/kg IV) to standard fentanyl premedication (1 mcg/kg IV) improves first-attempt success rates of tracheal intubation in newborns admitted to the NICU of Maternidade Ana Braga, Manaus, Brazil. The control group will receive fentanyl plus saline placebo. Sugammadex (16 mg/kg IV) is available as a reversal agent in case of prolonged neuromuscular blockade.
A secondary aim is to assess neonatologists' and residents' knowledge of and barriers to the use of neuromuscular blocking agents in neonatal intubation.
研究概览
地位
详细说明
Neonatal tracheal intubation is performed in approximately 15-20% of NICU admissions. First-attempt success rates are approximately 49%, and adverse tracheal intubation-associated events (TIAEs) occur in up to 18% of procedures, with severe oxygen desaturation in up to 48% (NEAR4NEOS registry, Foglia et al., 2019). Premedication with neuromuscular blocking agents has been independently associated with a 62% reduction in adverse events (aOR 0.38; 95% CI 0.25-0.57).
Rocuronium is a non-depolarizing neuromuscular blocking agent with rapid onset, stable hemodynamic profile, and full reversibility with sugammadex, making it a safe choice for neonatal premedication.
The NEORIN trial will enroll 102 newborns (51 per group) with postnatal age ≤28 days or corrected gestational age <44 weeks, requiring non-emergent tracheal intubation. Randomization will be performed in variable-sized permuted blocks (4 and 6), with allocation concealment through sequential opaque sealed envelopes.
Intervention group: fentanyl 1 mcg/kg IV + rocuronium 0.6 mg/kg IV. Control group: fentanyl 1 mcg/kg IV + saline placebo (equivalent volume). Sugammadex is available at the bedside throughout the study as a mandatory safety requirement.
The primary composite outcome is first-attempt intubation success without physiological instability, defined as correct tube placement on the first laryngoscopy attempt confirmed by colorimetric CO2 detection, with no SpO2 drop >20% from baseline and no bradycardia (HR <100 bpm). All procedures will be video-recorded for blinded outcome assessment.
A secondary descriptive study will assess neonatologists' and residents' knowledge of and barriers to neuromuscular blocking agent use in neonatal intubation, using a structured questionnaire applied before the start of the clinical trial.
研究类型
注册 (估计的)
阶段
- 第四阶段
联系人和位置
学习联系方式
- 姓名:JEFFERSON PEREIRA GUILHERME, M.D., Ph.D. candidate
- 电话号码:+55 92981228890
- 邮箱:jpguilherme@uea.edu.br
学习地点
-
-
Amazonas
-
Manaus、Amazonas、巴西、69057000
- Maternidade Ana Braga - UTI Neonatal
-
接触:
- JEFFERSON PEREIRA GUILHERME, M.D.; PhD candidate
- 电话号码:+55 92 981228890
- 邮箱:jpguilherme@uea.edu.br
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
接受健康志愿者
描述
Inclusion Criteria:
- Newborns admitted to the NICU, ≤28 postnatal days OR corrected gestational age <44 weeks
- Indication for non-emergent orotracheal intubation (≥5 minutes between decision to intubate and start of laryngoscopy)
- Informed consent signed by legal guardians
Exclusion Criteria:
- Upper airway malformations
- Use of neuromuscular blocking agent in the 24 hours prior to enrollment
- Known hypersensitivity to fentanyl or rocuronium
- Severe hemodynamic instability (ongoing shock)
- Anticipated difficult airway (micrognathia, cleft palate, or similar)
- Cyanotic congenital heart disease with critical instability
- Neonatal abstinence syndrome
- Concurrent enrollment in another interventional clinical trial
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Fentanyl + Rocuronium
Fentanyl 1 mcg/kg IV followed by rocuronium 0.6 mg/kg IV, administered sequentially before non-emergent tracheal intubation.
|
Rocuronium 0.6 mg/kg IV, single dose, administered as a bolus after fentanyl 1 mcg/kg IV, approximately 60 seconds before laryngoscopy
|
|
有源比较器:Fentanyl Only
Fentanyl 1 mcg/kg IV administered before non-emergent tracheal intubation, without neuromuscular blocking agent.
|
Rocuronium 0.6 mg/kg IV, single dose, administered as a bolus after fentanyl 1 mcg/kg IV, approximately 60 seconds before laryngoscopy
Fentanyl 1 mcg/kg IV, single dose, administered before non-emergent tracheal intubation in both groups.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
First-attempt intubation success without physiological instability
大体时间:During the intubation procedure, from first laryngoscopy attempt to confirmation of tube position (up to 5 minutes)
|
Composite outcome defined as correct endotracheal tube placement on the first laryngoscopy attempt, confirmed by colorimetric CO2 detection, with no SpO2 drop greater than 20% from baseline and no bradycardia (heart rate below 100 bpm) of any duration.
A new attempt is defined as removal and reinsertion of the laryngoscope blade into the oral cavity.
|
During the intubation procedure, from first laryngoscopy attempt to confirmation of tube position (up to 5 minutes)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Total number of intubation attempts
大体时间:During the intubation procedure, from first laryngoscopy attempt to successful intubation (up to 5 minutes)
|
Total number of laryngoscopy attempts required to achieve successful tracheal intubation, defined as each insertion of the laryngoscope blade into the oral cavity until its removal, regardless of tube insertion.
|
During the intubation procedure, from first laryngoscopy attempt to successful intubation (up to 5 minutes)
|
|
Procedure duration
大体时间:From first laryngoscopy attempt to confirmation of endotracheal tube position, assessed during the intubation procedure (up to 5 minutes)
|
Time in seconds from the first laryngoscopy attempt to confirmation of correct endotracheal tube position by colorimetric CO2 detection.
|
From first laryngoscopy attempt to confirmation of endotracheal tube position, assessed during the intubation procedure (up to 5 minutes)
|
|
Severe oxygen desaturation
大体时间:During the intubation procedure, from first laryngoscopy attempt to successful intubation (up to 5 minutes)
|
Occurrence of SpO2 drop greater than 20% from baseline value or SpO2 below 80%, at any point during the intubation procedure.
|
During the intubation procedure, from first laryngoscopy attempt to successful intubation (up to 5 minutes)
|
|
Bradycardia during intubation
大体时间:During the intubation procedure, from first laryngoscopy attempt to confirmation of tube position (up to 5 minutes)
|
Occurrence of heart rate below 100 bpm at any point during the intubation procedure.
|
During the intubation procedure, from first laryngoscopy attempt to confirmation of tube position (up to 5 minutes)
|
|
Need for additional maneuvers
大体时间:During the intubation procedure, from first laryngoscopy attempt to confirmation of tube position (up to 5 minutes)
|
Need for any additional maneuver during intubation, including external laryngeal manipulation, blade change, stylet use, or change of intubating physician.
|
During the intubation procedure, from first laryngoscopy attempt to confirmation of tube position (up to 5 minutes)
|
|
Medication-related adverse events
大体时间:During the intubation procedure, from first laryngoscopy attempt to confirmation of tube position (up to 5 minutes)
|
Occurrence of adverse events related to study medications, including hypotension, chest wall rigidity, allergic reactions, or need for sugammadex due to prolonged neuromuscular blockade.
|
During the intubation procedure, from first laryngoscopy attempt to confirmation of tube position (up to 5 minutes)
|
|
Knowledge and barriers to neuromuscular blocking agent use
大体时间:At the time of enrollment, before the intubation procedure, assessed once per participant
|
Score on a structured questionnaire assessing neonatologists' and residents' knowledge, attitudes, and barriers to the use of neuromuscular blocking agents in neonatal tracheal intubation.
Applied as a descriptive cross-sectional sub-study before the start of the clinical trial.
|
At the time of enrollment, before the intubation procedure, assessed once per participant
|
合作者和调查者
出版物和有用的链接
一般刊物
- Smith FJ, Holman CD, Moorin RE, Tsokos N. Lifetime risk of undergoing surgery for pelvic organ prolapse. Obstet Gynecol. 2010 Nov;116(5):1096-100. doi: 10.1097/AOG.0b013e3181f73729.
- Foglia EE, Ades A, Sawyer T, Glass KM, Singh N, Jung P, Quek BH, Johnston LC, Barry J, Zenge J, Moussa A, Kim JH, DeMeo SD, Napolitano N, Nadkarni V, Nishisaki A; NEAR4NEOS Investigators. Neonatal Intubation Practice and Outcomes: An International Registry Study. Pediatrics. 2019 Jan;143(1):e20180902. doi: 10.1542/peds.2018-0902. Epub 2018 Dec 11.
- Lin JD, Fang WF, Tang KT, Cheng CW. Effects of exogenous melatonin on clinical and pathological features of a human thyroglobulin-induced experimental autoimmune thyroiditis mouse model. Sci Rep. 2019 Apr 10;9(1):5886. doi: 10.1038/s41598-019-42442-0.
- Krick J, Gray M, Umoren R, Lee G, Sawyer T. Premedication with paralysis improves intubation success and decreases adverse events in very low birth weight infants: a prospective cohort study. J Perinatol. 2018 Jun;38(6):681-686. doi: 10.1038/s41372-018-0082-2. Epub 2018 Feb 21.
- Herrick HM, Glass KM, Johnston LC, Singh N, Shults J, Ades A, Nadkarni V, Nishisaki A, Foglia EE; for the NEAR4NEOS Investigators. Comparison of Neonatal Intubation Practice and Outcomes between the Neonatal Intensive Care Unit and Delivery Room. Neonatology. 2020;117(1):65-72. doi: 10.1159/000502611. Epub 2019 Sep 27.
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- NEORIN-2026-MAB/UEA
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.